Acute lymphoblastic leukaemia: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• CD19 121
• CD22 32
• ABL1 10
• KMT2A 8
• CD20 8
• TP53 0
• AKT 0
• BCL-2 3
• PI3K 0
• CD123 5
• JAK 2
• CD38 4
• PD-1 3
• RUNX1 0
• mTOR 0
• NPM1 4
• BCMA 4
• NOTCH1 0
• CXCR4 1
• PTEN 0
• CTNNB1 0
• EGFR 0
• HDAC 0
• IDH 0
• MYC 0
• RAS 0
• STAT3 0
• AMPK 0
• CD30 0
• CD40 0
• CD47 0
• ERK 0
• FGFR 0
• MAPK 0
• MDM2 0
• PD-L1 0
• CD33 1
• FLT3 0
• IL-1 0
• IL-17 0
• IL-6 0
• KRAS 0
• MEK 0
• PPAR 0
• RANKL 0
• RB1 0
• TYK2 0
• ALK 0
• AXL 0
• BRCA1 0
• BRD4 0
• BTK 0
• CDK4/6 0
• CDKN2A 0
• CTLA-4 0
• EZH2 0
• FAK 0
• FTO 0
• GPRC5D 1
• GPX4 0

EU-13 is a filter, not a ranking: it only narrows the list.

5 of 5+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Obinutuzumab Versus Rituximab for Acute Lymphoblastic Leukemia/PALG ALL7 "OVERALL"

  NCT04920968· Maria Sklodowska-Curie National Research Institute of Oncology· Updated 15 Oct 2026

  “Following the recommendation of the Data Monitoring Committee (DMC), based on the results of the interim analysis, the Sponsor has decided to terminate the study prematurely”Registry text, quoted unchanged. Source

• Terminated

  CAR-20/19-T Cells in Patients With Relapsed/Refractory B Cell ALL

  NCT04049383· Medical College of Wisconsin· Updated 12 Jan 2026

  “Low accrual”Registry text, quoted unchanged. Source

• Terminated

  A Triple-targeted Cell Preparation Targeting CD19/CD20/CD22 in Patients With Relapsed/Refractory B-cell Acute Lymphocytic Leukemia

  NCT05292898· Institute of Hematology & Blood Diseases Hospital, China· Updated 3 Jun 2025

  “Achieve the proof of concept”Registry text, quoted unchanged. Source

• Terminated

  First-in-Human (FIH) Trial of 1A46 in Subjects with Advanced CD20 And/or CD19 Positive B-cell Hematologic Malignancies

  NCT05348889· Chimagen Biosciences, Ltd· Updated 13 Feb 2025

  “Sponsor's Research and Development strategy adjustment”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 6
• Mendelian Randomization Analysis 4
• CRISPR-Cas Systems 5
• Gene Expression Profiling 27
• Sequence Analysis, RNA 2
• Whole Genome Sequencing 1
• Exome Sequencing 1
• Proteomics 7
• Metabolomics 4
• Flow Cytometry 40
• Immunohistochemistry 6
• Circulating Tumor DNA 1
• Xenograft Model Antitumor Assays 50
• Magnetic Resonance Imaging 14
• Machine Learning 11
• Deep Learning 8
• Cohort Studies 26
• Genome-Wide Association Study 8

• An Artificial Intelligence Framework for Detection of Leukemia with Comparison Between Segmented and Non-Segmented Images.

  Sensors (Basel), Oct 2026

• ClinNetDx: a novel explainable ai framework for acute lymphoblastic leukemia detection using multi-modal clinical data.

  BMC Cancer, Jul 2026

• Detection of acute lymphocytic and myeloid leukaemia with optimized dimensionality reduction and deep learning classification framework.

  Curr Res Transl Med, Jun 2026

• An explainable meta-learned hybrid CNN-transformer model with dual attention for leukemia diagnosis from peripheral blood smears.

  Sci Rep, Jun 2026

• A systematic review of machine and deep learning techniques for acute lymphoblastic leukemia diagnosis.

  Artif Intell Med, Mar 2026

• Improving acute lymphoblastic leukemia diagnosis through CBAM-enhanced VGG19 deep learning.

  Sci Rep, Feb 2026

• Reliable leukemia detection via transfer-enhanced Bayesian CNNs.

  Comput Biol Med, Jan 2026

• Blast cell segmentation and leukemia classification using hybrid Deep Kronecker WideResNet using blood smear images.

  Comput Biol Chem, Nov 2025

See which targets of this disease your abstract mentions, and go to the people working on them.